MoU / CRA
Memorandum of Agreement to “Develop a Machine Learning (ML) / Artificial Intelligence (AI) model to detect beta thalassemia trait using CBC parameters” with ICMR-National Institute of Immunohematology (NIIH), KEM Hospital Campus, Parel, Mumbai for 1 year from 8th March, 2023. Scientists from NIIH – Dr. Manisha Madkaikar and Dr. Naveen Khargekar; Scientists from BITS Goa – Dr. Snehanshu Saha.
Collaborative Research Agreement on "Pathophysiological investigations of Sickle Cell Disease and Interventions to improve associated Hemorheological Abnormalities" with Sri Sri College of Ayurvedic Science and Research Hospital, Sri Sri University, Cuttack, Odisha for 5 years from December 9, 2021.
Collaborative Research Agreement (CRA or MoU) with M/s Sai Phytoceuticals Pvt. Ltd, New Delhi, India for the project entitled “Pathophysiological investigations of sickle cell disease and interventions to improve associated hemorheological abnormalities”, for 5 years from 20th October, 2021
Collaborative Research Agreement (CRA or MoU) effective from 11th December, 2020 with M/s Sai Phytoceuticals Pvt. Ltd., Greater Kailash Part II, New Delhi 110048 (Mr Anil Bhansali) on the topic “New Drug Candidates to Combat Hypertension and Cardiac Hypertrophy Designed against an Unconventional Target and Pathway”
Collaborative Research Agreement (CRA or MoU) effective from 7th November, 2017 for 5 years with All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029 (Prof. S.K Maulik, Department of Pharmacology) on the topic “Scientific validation of medicinal plant extracts and their constituents in regulating pulmonary and systemic hypertension vis-à-vis catecholamine biosynthetic, NO metabolism and redox pathways”
Collaborative Research Agreement (CRA or MoU) effective from 7th November, 2017 for 5 years with All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029 (Prof. S.K Maulik, Department of Pharmacology) on the topic “Development and screening of potent small molecule inhibitors against dopamine beta-hydroxylase and nicotinamide adenine dinucleotide phosphate oxidase to combat pulmonary hypertension”
An Institute of Eminence
